Intellia Therapeutics, Inc. (NTLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$12.21-4.16%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Intellia is advancing Lonvo-z for hereditary angioedema treatment. Revenue is expected above $67 million in 2026. The company aims to extend cash to 2028. Recent positive trial results support future growth.
The company is still loss-making with negative EPS. Litigation risks exist from recent filings. Revenue growth depends on successful drug approvals. Cash runway extension is uncertain.
The price is about 9% below our fair value near $19. Analysts expect about 49% revenue growth. Our fair value is below the Street median, reflecting caution.
Breaks if: Progress stalls or trial results turn negative
Breaks if: Cash runway falls short of 2028
Breaks if: Revenue falls below $67 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is working on important clinical trials and regulatory submissions that could drive future growth.
The market appears to have priced in a low expectations gap, indicating that investors may not be anticipating significant positive surprises. Valuation shows a premium compared to peers, suggesting that some growth potential is already reflected in the current setup.
Management is focused on advancing treatments like Lonvo-z for HAE and Nex-z for ATTR amyloidosis. While recent financial performance has been neutral, the company has maintained a stable cash position, which is crucial for funding operations into 2028.
The long-term thesis hinges on the successful advancement of clinical trials and regulatory approvals, as well as the overall health of the healthcare sector. Key triggers include guidance updates and performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The advancement of Lonvo-z for HAE treatment supports the thesis. Additionally, the FDA's priority review reinforces this positive outlook. There are no new threats identified that could weaken the read.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, NTLA's success will depend on its ability to execute on its clinical and financial strategies amid a challenging market backdrop. Not investment advice.